Results of COVID-minimal Surgical Pathway During Surge-phase of COVID-19 Pandemic.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 22 10 2020
medline: 15 12 2020
entrez: 21 10 2020
Statut: ppublish

Résumé

The outcomes of patients treated on the COVID-minimal pathway were evaluated during a period of surging COVID-19 hospital admissions, to determine the safety of continuing to perform urgent operations during the pandemic. Crucial treatments were delayed for many patients during the COVID-19 pandemic, over concerns for hospital-acquired COVID-19 infections. To protect cancer patients whose survival depended on timely surgery, a "COVID-minimal pathway" was created. Patients who underwent a surgical procedure on the pathway between April and May 2020 were evaluated. The "COVID-minimal surgical pathway" consisted of: (A) evolving best-practices in COVID-19 transmission-reduction, (B) screening patients and staff, (C) preoperative COVID-19 patient testing, (D) isolating pathway patients from COVID-19 patients. Patient status through 2 weeks from discharge was determined as a reflection of hospital-acquired COVID-19 infections. After implementation, pathway screening processes excluded 7 COVID-19-positive people from interacting with pathway (4 staff and 3 patients). Overall, 122 patients underwent 125 procedures on pathway, yielding 83 admissions (42 outpatient procedures). The median age was 64 (56-79) and 57% of patients were female. The most common surgical indications were cancer affecting the uterus, genitourinary tract, colon, lung or head and neck. The median length of admission was 3 days (1-6). Repeat COVID-19 testing performed on 27 patients (all negative), including 9 patients evaluated in an emergency room and 8 readmitted patients. In the postoperative period, no patient developed a COVID-19 infection. A COVID-minimal pathway comprised of physical space modifications and operational changes may allow urgent cancer treatment to safely continue during the COVID-19 pandemic, even during the surge-phase.

Sections du résumé

OBJECTIVE
The outcomes of patients treated on the COVID-minimal pathway were evaluated during a period of surging COVID-19 hospital admissions, to determine the safety of continuing to perform urgent operations during the pandemic.
SUMMARY OF BACKGROUND DATA
Crucial treatments were delayed for many patients during the COVID-19 pandemic, over concerns for hospital-acquired COVID-19 infections. To protect cancer patients whose survival depended on timely surgery, a "COVID-minimal pathway" was created.
METHODS
Patients who underwent a surgical procedure on the pathway between April and May 2020 were evaluated. The "COVID-minimal surgical pathway" consisted of: (A) evolving best-practices in COVID-19 transmission-reduction, (B) screening patients and staff, (C) preoperative COVID-19 patient testing, (D) isolating pathway patients from COVID-19 patients. Patient status through 2 weeks from discharge was determined as a reflection of hospital-acquired COVID-19 infections.
RESULTS
After implementation, pathway screening processes excluded 7 COVID-19-positive people from interacting with pathway (4 staff and 3 patients). Overall, 122 patients underwent 125 procedures on pathway, yielding 83 admissions (42 outpatient procedures). The median age was 64 (56-79) and 57% of patients were female. The most common surgical indications were cancer affecting the uterus, genitourinary tract, colon, lung or head and neck. The median length of admission was 3 days (1-6). Repeat COVID-19 testing performed on 27 patients (all negative), including 9 patients evaluated in an emergency room and 8 readmitted patients. In the postoperative period, no patient developed a COVID-19 infection.
CONCLUSIONS
A COVID-minimal pathway comprised of physical space modifications and operational changes may allow urgent cancer treatment to safely continue during the COVID-19 pandemic, even during the surge-phase.

Identifiants

pubmed: 33086321
doi: 10.1097/SLA.0000000000004455
pmc: PMC7668334
pii: 00000658-202012000-00056
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e316-e320

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Références

Grotenhuis BA, van Hagen P, Wijnhoven BP, et al. Delay in diagnostic workup and treatment of esophageal cancer. J Gastrointest Surg 2010; 14:476–483.
Samson P, Crabtree TD, Robinson CG, et al. Defining the ideal time interval between planned induction therapy and surgery for stage IIIA non-small cell lung cancer. Ann Thorac Surg 2017; 103:1070–1075.
Grass F, Behm KT, Duchalais E, et al. Impact of delay to surgery on survival in stage I-III colon cancer. Eur J Surg Oncol 2020; 46:455–461.
ACS Guidelines for Triage and Management of Elective Cancer Surgery Cases During the Acute and Recovery Phases of Coronavirus Disease 2019 (COVID-19) Pandemic May 7, 2020. 2020. Available at: https://www.facs.org/-/media/files/covid19/acs_triage_and_management_elective_cancer_surgery_during_acute_and_recovery_phases.ashx. Accessed June 3, 2020.
Thoracic Surgery Outcomes Research Network, Inc, Antonoff M, Backhus L, Boffa DJ, et al. COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement From Thoracic Surgery Outcomes Research Network. Ann Thorac Surg. 2020;110:692–696.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708–1720.
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; 395:1907–1918.
Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 2020; 21:100331doi: 10.1016/j.eclinm.2020.100331.
doi: 10.1016/j.eclinm.2020.100331
Aminian A, Safari S, Razeghian-Jahromi A, Ghorbani M, Delaney CP. COVID-19 outbreak and surgical practice: unexpected fatality in perioperative period. Ann Surg 2020; 272:e27–e9.
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21:335–337.
Collaborative CO. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet 2020; 396:27–38.
Boffa DJ, Judson BL, Billingsley KG, et al. Pandemic recovery using a COVID-minimal cancer surgery pathway. Ann Thorac Surg 2020; 110:718–724.
Qin J, You C, Lin Q, Hu T, Yu S, Zhou XH. Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study. medRxiv 2020.
Li YK, Peng S, Li LQ, et al. Clinical and transmission characteristics of Covid-19 - a retrospective study of 25 cases from a single thoracic surgery department. Curr Med Sci 2020; 40:295–300.
Luong-Nguyen M, Hermand H, Abdalla S, et al. Nosocomial infection with SARS-Cov-2 within Departments of Digestive Surgery. J Visc Surg 2020.
McDermott A, O’Kelly J, de Barra E, et al. Perioperative outcomes of urological surgery in patients with SARS-CoV-2 infection. Eur Urol 2020; 78:118–120.
Lee LYW, Cazier JB, Starkey T, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020; 395:1919–1926.
Lin EE, Blumberg TJ, Adler AC, et al. Incidence of COVID-19 in pediatric surgical patients among 3 US children's hospitals. JAMA Surg 2020.
Worldometer. COVID-19 Coronavirus Pandemic June 2, 2020, 2020. 2020. Available at: https://www.worldometers.info/coronavirus/. Accessed June 3, 2020.
Prevention CfDCa. How Covid-19 Spreads 4/13/2020, 2020. Accessed April, 23, 2020.
Organization WH. Basic Protective Measures Against the New Coronavirus 3/31/2020, 2020. Accessed April, 23, 2020.
Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med 2020; 173:262–267.
Al-Shamsi HO, Coomes EA, Alrawi S. Screening for COVID-19 in asymptomatic patients with cancer in a hospital in the United Arab Emirates. JAMA Oncol 2020.

Auteurs

Daniel J Boffa (DJ)

Smilow Cancer Hospital, Yale New Haven Hospital, New Haven, Connecticut.
Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Benjamin L Judson (BL)

Smilow Cancer Hospital, Yale New Haven Hospital, New Haven, Connecticut.
Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Kevin G Billingsley (KG)

Smilow Cancer Hospital, Yale New Haven Hospital, New Haven, Connecticut.
Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Erin Del Rossi (E)

Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Kasey Hindinger (K)

Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Samantha Walters (S)

Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Theresa Ermer (T)

Faculty of Medicine, Friedrich-Alexander-University, Erlangen-Nürnberg, Germany.

Elena Ratner (E)

Department of Obstetrics and Gynecology, Yale School of Medicine, New Haven, Connecticut.

Marci R Mitchell (MR)

Smilow Cancer Hospital, Yale New Haven Hospital, New Haven, Connecticut.

Maxwell S Laurans (MS)

Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut.

Dirk C Johnson (DC)

Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Peter S Yoo (PS)

Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

John M Morton (JM)

Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Holly B Zurich (HB)

Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Kimberly Davis (K)

Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Nita Ahuja (N)

Department of Surgery, Yale School of Medicine, New Haven, Connecticut.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH